Tokai Pharmaceuticals Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Tokai Pharmaceuticals's estimated annual revenue is currently $5.1M per year.(i)
  • Tokai Pharmaceuticals's estimated revenue per employee is $155,000

Employee Data

  • Tokai Pharmaceuticals has 33 Employees.(i)
  • Tokai Pharmaceuticals grew their employee count by 14% last year.

Tokai Pharmaceuticals's People

NameTitleEmail/Phone
1
VP, Technical OperationsReveal Email/Phone
2
VP, BiometricsReveal Email/Phone
3
President and Chief Scientific OfficerReveal Email/Phone
4
General Counsel, Chief Compliance Officer, & Corporate SecretaryReveal Email/Phone
5
Chief Financial OfficerReveal Email/Phone
6
Director Project ManagementReveal Email/Phone
7
Chief Regulatory OfficerReveal Email/Phone
8
Senior Clinical Project ManagerReveal Email/Phone
9
Project Manager ContractReveal Email/Phone
10
Clinical Project ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Tokai Pharmaceuticals?

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. Our lead program, AT-1501, is a potential best-in-class humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.

keywords:N/A

N/A

Total Funding

33

Number of Employees

$5.1M

Revenue (est)

14%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Tokai Pharmaceuticals News

2022-04-13 - Evolving Role of Prostate-Specific Membrane Antigen ...

Honoraria: Research to Practice, Astellas Pharma, AstraZeneca, ... Janssen Oncology, Tokai Pharmaceuticals, Astellas Pharma, Incyte, Pfizer,...

2022-04-13 - Evolving Role of Prostate-Specific Membrane Antigen ...

Honoraria: Research to Practice, Astellas Pharma, AstraZeneca, ... Janssen Oncology, Tokai Pharmaceuticals, Astellas Pharma, Incyte, Pfizer,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.8M336%N/A
#2
$5.1M333%N/A
#3
$5.1M3314%N/A
#4
$3.8M33-8%N/A
#5
$5.8M33-6%N/A